Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis

Angelo Andriulli, Gioacchino Leandro, Telemaco Federici, Antonio Ippolito, Rosario Forlano, Angelo Iacobellis, Vito Annese

Research output: Contribution to journalArticlepeer-review


Background: The prophylactic use of somatostatin or gabexate in patients undergoing ERCP is still controversial. Objective: Our purpose was to update the meta-analysis on somatostatin (SS, 16 studies) or gabexate mesylate (GM, 9 studies) prophylaxis of post-ERCP pancreatitis and to run sensitivity analyses by subgrouping trials according to schedules of drug administration. Main Outcome Measurements: Post-ERCP acute pancreatitis, hyperamylasemia, and pain. Results: Heterogeneity was present among selected studies, which appeared eliminated when only 9 high-quality trials on SS and 5 randomized studies on GM were considered. After data were pooled from SS trials, pancreatitis occurred in 7.3% of controls versus 5.3% of treated patients, a nonsignificant effect (odds ratio [OR] = 0.73; 95% CI 0.54-1.006). The funnel plot showed asymmetry with a negative slope (P = .05). The meta-analysis produced negative results for either short- (12 hours) GM administration. Conclusion: Short- or long-term infusion of SS or GM proved ineffective in reducing post-ERCP pancreatitis and pain. The beneficial effect of SS on postprocedural hyperamylasemia seems of marginal significance. When given as a bolus injection, SS maintains its promise in this field, but additional data are needed.

Original languageEnglish
Pages (from-to)624-632
Number of pages9
JournalGastrointestinal Endoscopy
Issue number4
Publication statusPublished - Apr 2007

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis'. Together they form a unique fingerprint.

Cite this